As large multi-cancer datasets become more important for predicting who may benefit from cancer drugs, a new approach better accounts for potentially overlooked variation.
A team explores the possible association between genetic variants in the human genome and liver attenuation.
A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.
Targeting this inside-the-cell checkpoint could potentially improve response to cancer immunotherapy.
Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.